

# CURRICULUM VITAE



## PERSONAL INFORMATION

Name **Sara PILOTTO**  
Adress **VIA MERCIARI 5, 37135, VERONA, ITALIA**  
Telephone **+39 3489116667**  
**+39 0458128124**  
Fax **+390458128140**  
E-mail [sara.pilotto@univr.it](mailto:sara.pilotto@univr.it)  
[sara.pilotto.85@gmail.com](mailto:sara.pilotto.85@gmail.com)  
Nationality **Italian**  
Date of birth **APRIL 24TH, 1985**

## WORK EXPERIENCE

- Date (from-to) **From May 2010 to May 2015**
- Name and address of employer **Department of Medical Oncology, University of Verona (ITALY),  
Director Prof. Giampaolo Tortora, M.D., Ph.D**
- Occupation or position held **Medical Oncologist Resident Doctor**
  
- Date (from-to) **From October 2015**
- Name and address of employer **Department of Medical Oncology, University of Verona (ITALY),  
Director Prof. Giampaolo Tortora, M.D., Ph.D**
- Occupation or position held **Medical Oncologist, PhD student**
  
- Date (from-to) **From December 2016**
- Name and address of employer **Department of Medical Oncology, University of Verona (ITALY),  
Director Prof. Giampaolo Tortora, M.D., Ph.D**
- Occupation or position held **Medical Oncologist, Academic Researcher**

## EDUCATION AND TRAINING

- Date (from-to) **2003/4 – 2008/9**
- Name and type of education and training **Degree course in Medicine and surgery at Verona University (ITALY)**
  - 2007 – 2009: Department of Medical Oncology, University of Verona (ITALY), Director Prof. Gianluigi Cetto, as internal student.
  - March - October 2009: Department of Immunology (Department Director Prof. M. Colombatti) at Verona University as Pre-doctoral Fellow. Experiences in molecular biology, cell cultures, in vivo models (xenografts).
  
- Title of qualification awarded **October 15, 2009: Degree in Medicine and Surgery with Full Marks and Honors (110/110 cum laude) at Verona University (ITALY)**

- Experimental thesis: PSMA (prostate specific membrane antigen) e mesotelina: approcci innovativi di immunotargeting in neoplasia solide umane". Chairman: Prof. G.L. Cetto.
- Date (from-to) February 2010: Italian Medical License Exam (IMLE) at University of Verona (ITALY)
- Date (from-to) From May 2010 to May 2015
- Name and type of education and training Medical Oncology Residency  
Department of Medical Oncology, University of Verona (ITALY),  
Director Prof. Giampaolo Tortora, M.D., Ph.D
- Title of qualification awarded June 10, 2015: **Specialistic Degree** in Medical Oncology with Full Marks and Honors (*70/70 cum laude*) at Verona University (ITALY)
  - Experimental thesis: "Molecular characterization of advanced EGFR mutant lung adenocarcinoma with Next-Generation Sequencing and Digital PCR: correlation with activity and efficacy of gefitinib". Chairman: Prof. Giampaolo Tortora, M.D., Ph.D
- Date (from-to) From April 2015 to February 2016: **training experience** at the Istituto Oncologico Dr. Rosell - Hospital Universitario Quiron Dexeus (Barcelona) about the preclinical and translational aspects of lung cancer research.
- Date (from-to) From October 2015: **PhD program** in Inflammation, Immunity and Cancer.
  - Project title: Genetic, epigenetic and micro-environmental markers as predictors of prognosis, response and resistance to chemotherapy, targeted agents and immunotherapy in resected squamous cell lung carcinoma.

## PERSONAL SKILLS AND COMPETENCES

### Prizes and Awards

- 2015 - Winner of the International Association for the Study of Lung Cancer (IASLC) Fellowship Award.  
  
Project title: Immune checkpoint inhibitor and driving gene mutations as outcome predictors for resected squamous cell lung carcinoma.
- From 2014 involved as co-investigator in the Italian Association for Cancer Research (AIRC, My First AIRC Grant n° 14282) (P.I. Prof. Bria)
- Course of Medical Statistic in the University of Verona (April 2014)
- Accepted at the 2<sup>nd</sup> ETOP Residential Workshop, Lugano, Switzerland, August 2013 (residential workshop for young investigators in the field of thoracic malignancies)

Reviewer for several Peer-Reviewed journals (Immunotherapy, Expert Opinion on Biological Therapy, Targeted Oncology, Plos One, The International Journal of Biological Markers, Translational lung cancer research)

### Participation in experimental clinical trials

- From 2012 involved as sub-investigator in several clinical trials:
- Fase I: CTKI258A2124 Hepatic impairment study (dovitinib).
  - Fase II: ETOP 2-11 BELIEF trial (bevacizumab + erlotinib), CLDK378A2205 and CLDK378A2112 (ceritinib), TEMPO LUNG 01 (vinorelbine metronomic), CINC 28A2201 and CINC 280B2201 (INC280), SENECA (nintedanib).
  - Fase III: EPIC, MILES-4, MILES-3 (personalized chemotherapy in old patients), OAK GO28915 (atezolizumab), KEYNOTE-189 (pembrolizumab), BEVERLY (bevacizumab + erlotinib), METROS (crizotinib), BR.31 (MEDI4736), ASTRIS (AZD9291).

## **Publications**

### **First author in 18 original scientific publications on Peer-Reviewed journals:**

- **Pilotto S**, Sperduti I, Leuzzi G, Chiappetta M, Mucilli F, Ratto GB, Lococo F, Filosso P, Spaggiari L, Novello S, Milella M, Santo A, Scarpa A, Infante M, Tortora G, Facciolo F, Bria E. Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. *J Thorac Oncol*. 2017 Dec 18. pii: S1556-0864(17)33101-5.
- **Pilotto S**, Carbognin L, Karachaliou N, Ma PC, Rosell R, Tortora G, Bria E. Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. *Cancer Treat Rev*. 2017 Aug 20;60:1-11.
- **Pilotto S**, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, Novello S. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. *Clin Lung Cancer*. 2017 Jun 1 (*and corresponding author*)
- **Pilotto S**, Gkountakos A, Carbognin L, Scarpa A, Tortora G, Bria E. MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. *Ann Transl Med*. 2017 Jan;5(1):2.
- Bria E\*, **Pilotto S\***, Simbolo M, Fassan M, de Manzoni G, Carbognin L, Sperduti I, Brunelli M, Cataldo I, Tomezzoli A, Mafficini A, Turri G, Karachaliou N, Rosell R, Tortora G, Scarpa A. Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis. *Sci Rep*. 2016 Mar 10; 6:22982.
- Ferrara R\*, **Pilotto S\***, Peretti U, Caccese M, Kinspergher S, Carbognin L, Karachaliou N, Rosell R, Tortora G, Bria E. Tubulin inhibitors in Non-Small Cell Lung Cancer: looking back and forward. *Expert Opin Pharmacother*. 2016 Jun; 17(8): 1113-29.
- **Pilotto S**, Carbognin L, Karachaliou N, Garassino M, Cuppone F, Petraglia S, Rosell R, Tortora G, Bria E. Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. *Transl Lung Cancer Res* 2015 Dec;4(6):704-12.
- **Pilotto S**, MA Molina-Vila, Karachaliou N, Carbognin L, Viteri S, Gonzalez Cao M, Bria E, Tortora G, Rosell R. Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. *Transl Lung Cancer Res* 2015 Dec;4(6):721-7.
- **Pilotto S**, Novello S, Peretti U, Kinspergher S, Ciuffreda L, Milella M, Carbognin L, Vavalà T, Ferrara R, Caccese M, Tortora G, Bria E. An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. *Expert Opin Investig Drugs* 2015 Sep;24(9):1143-61.
- **Pilotto S**, Sperduti I, Novello S, Peretti U, Milella M, Facciolo F, Vari S, Leuzzi G, Vavalà T, Marchetti A, Mucilli F, Crinò L, Puma F, Kinspergher S, Santo A, Carbognin L, Brunelli M, Chilosi M, Scarpa A, Tortora G, Bria E. Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. *J Thorac Oncol* 2015 Sep;10(9):1341-8.
- Calvetti L\*, **Pilotto S\***, Carbognin L, Ferrara R, Caccese M, Tortora G, Bria E. The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. *Expert Opin Biol Ther* 2015 Sep;15(9):1359-70
- Bria E\*, **Pilotto S\***, Amato E, Fassan M, Novello S, Peretti U, Vavalà, Kinspergher S, Righi L, Santo A, Brunelli M, Corbo V, Giglioli E, Sperduti I, Milella M, Chilosi M, Scarpa A, Tortora G. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. *Oncotarget* 2015 Mar 30.
- **Pilotto S**, Kinspergher S, Peretti U, Caliò A, Carbognin L, Ferrara R, Brunelli M, Scarpa A, Tortora G, Bria E. Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? *Anticancer Agents Med Chem* 2015 15 (3): 307-13.
- **Pilotto S**, Bria E, Peretti U, Massari F, Garassino M, Pelosi G, Tortora G. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. *J Thorac Oncol*, 2013 vol. 8 (12); 105-6.
- **Pilotto S**, Di Maio M, Peretti U, Kinspergher S, Brunelli M, Massari F, Sperduti I, Giannarelli D, De Marinis F, Tortora G, Bria E. Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: sensitivity and meta-regression analysis of randomized trials. *Crit Rev Oncol Hematol* 2014; 90 (2): 135-145.

- **Pilotto S**, Bonomi M, Massari F, Milella M, Ciuffreda L, Brunelli M, Fassan M, Chilosi M, Scarpa A, Tortora G, Bria E. Anti-Angiogenic Drugs and Relative Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night'. *Current Pharmaceutical Designs* 2014; 20 (24): 3958-72.
- **Pilotto S**, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. *Expert Opin Pharmacother*. 2013 Apr;14(5):597-608.
- **Pilotto S**, Bria E. Predictors of outcome for EGFR mutant non-small cell lung cancer treated with 1st-line tyrosine kinase inhibitors. *Lung Cancer Management* 2013. April 2013, Vol. 2, No. 2, Pages 89-92.

**Corresponding and/or last author in 4 original scientific publications on Peer-Reviewed journals:**

- Grizzi G, Caccese M, Gkoutakos A, Carbognin L, Tortora G, Bria E, **Pilotto S**. Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. *Expert Rev Mol Diagn*. 2017 Oct 23:1-15.
- Benato, C, **Pilotto S**, Infante M, Bria E. Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. *Journal of Thoracic Disease* Volume 9, Issue 9, 1 September 2017, Pages 2743-2745.
- Peretti U, Ferrara R, **Pilotto S**, Kinspergher S, Caccese M, Santo A, Brunelli M, Caliò A, Carbognin L, Sperduti I, Chilosi M, Scarpa A, Tortora G, Bria E. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. *Respir Res*. 2016 Aug 25;17(1):105.
- Ferrara R, Caccese M, Cuppone F, Bria E, Tortora G, **Pilotto S**. Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? *Accepted Transl Cancer Res* 2016.

**Co-author in 34 original scientific publications on Peer-Reviewed journals:**

- Carbognin L, Sperduti I, Fabi A, Dieci MV, Kadrija D, Griguolo G, **Pilotto S**, Guarneri V, Zampiva I, Brunelli M, Orvieto E, Nortilli R, Fiorio E, Parolin V, Manfrin E, Caliò A, Nisticò C, Pellini F, Scarpa A, Pollini GP, Conte P, Tortora G, Bria E. Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. *Breast*. 2017 Oct;35:21-26.
- Capelletto E, Rapetti SG, Demichelis S, Galetta D, Catino A, Ricci D, Moretti AM, Bria E, **Pilotto S**, Bruno A, Valmadre G, Bandelli GP, Trisolini R, Gianetta M, Pacchiana MV, Vallone S, Novello S. Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease. *Clin Respir J*. 2017 May 2.
- Chaib I, Karachaliou N, **Pilotto S**, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, Reguart N, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. *J Natl Cancer Inst*. 2017 Sep 1;109(9).
- Brunelli M, Eccher A, Cima L, Trippini T, Pedron S, Chilosi M, Barbareschi M, Scarpa A, Pinna G, Cabrini G, **Pilotto S**, Carbognin L, Bria E, Tortora G, Fioravanzo A, Schiavo N, Meglio M, Sava T, Belli L, Martignoni G, Ghimenton C. Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors. *Cancer Genet*. 2017 Jan;210:28-33.
- Zambonin V, De Toma A, Carbognin L, Nortilli R, Fiorio E, Parolin V, **Pilotto S**, Cuppone F, Pellini F, Lombardi D, Pollini GP, Tortora G, Bria E. Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research. *Expert Opin Biol Ther*. 2017 Apr;17(4):497-506.
- Caliò A, Bria E, **Pilotto S**, Gilioli E, Nottegar A, Eccher A, Cima L, Santo A, Pedron S, Turri G, Knuutila S, Chilosi M, Vanzo F, Bogina G, Terzi A, Tortora G, Scarpa A, Loda M, Martignoni G, Brunelli M. ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes. *Cancer Biomark*. 2017;18(2):215-220.
- Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, Mastracci L, Rusev B, Grillo F, Vicentini C, Ferrara R, **Pilotto S**, Davini F, Pelosi G, Lawlor RT, Chilosi M, Tortora G, Bria E, Fontanini G, Volante M, Scarpa A Lung neuroendocrine tumours: deep

sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. *J Pathol*. 2017 Mar;241(4):488-500.

- Caccese M, Ferrara R, **Pilotto S**, Carbognin L, Grizzi G, Calìo A, Brunelli M, Cuppone F, Petraglia S, Scarpa A, Tortora G, Bria E. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. *Expert Opin Pharmacother*. 2016 Dec;17(17):2253-2266.
- Carbognin L, Sperduti I, Ciccarese M, Fabi A, Petrucelli L, Vari S, Forcignanò RC, Nortilli R, Vicentini C, **Pilotto S**, Merler S, Zampiva I, Brunelli M, Manfrin E, Giannarelli D, Tortora G, Bria E. Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: implications for post-progression and conditional survival. *Breast*. 2016 Jul 7; 29: 24-30.
- Carbognin L, **Pilotto S**, Peretti U, Tortora G, Bria E. Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? *Expert Opin Investig Drugs*. 2016 Jun; 25(6): 635-8.
- Lazzari C, Verlicchi A, Gkoutakos A, **Pilotto S**, Santarpia M, Chaib I, Ramirez Serrano JL, Viteri S, Morales-Espinosa D, Dazzi C, de Marinis F, Cao P, Karachaliou N, Rosell R. Molecular bases for combinatorial treatment strategies in patients with KRAS mutant lung adenocarcinoma and lung squamous cell carcinoma. *Pulm Ther* 2016; DOI 10.1007/s41030-016-0013-3.
- Carbognin L, Sperduti I, Brunelli M, Marcolini L, Nortilli R, **Pilotto S**, Zampiva I, Merler S, Manfrin E, Pellini F, Bonetti F, Pollini GP, Tortora G, Bria E. Subpopulation treatment effect pattern plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer. *J Exp Clin Cancer Res*. 2016 Mar 22; 35:50.
- Carbognin L, **Pilotto S**, Nortilli R, Brunelli M, Nottesgar A, Sperduti I, Giannarelli D, Bria E, Tortora G. Predictive and prognostic role of tumor-infiltrating lymphocytes for early breast cancer according to disease subtypes: sensitivity analysis of randomized trials in adjuvant and neoadjuvant setting. *Oncologist*. 2016 Mar; 21(3): 283-91.
- Karachaliou N, **Pilotto S**, Lazzari C, Bria E, de Marinis F, Rosell R. Cellular and molecular biology of small cell lung cancer: an overview. *Transl Lung Cancer Res*. 2016 Feb;5(1):2-15.
- Karachaliou N, Codony-Servat J, Teixidó C, **Pilotto S**, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. *Sci Rep*. 2015 Dec 7;5:17499.
- Massari F, Modena A, Ciccarese C, **Pilotto S**, Maines F, Bracarda S, Sperduti I, Giannarelli D, Carlini P, Santini D, Tortora G, Porta C, Bria E. Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. *Crit Rev Oncol Hematol*. 2016 Feb;98:254-63.
- González-Cao M, Rodón J, Karachaliou N, Sánchez J, Santarpia M, Viteri S, **Pilotto S**, Teixidó C, Riso A, Rosell. Other targeted drugs in melanoma. *Ann Transl Med*. 2015 Oct;3(18):266.
- Karachaliou N, **Pilotto S**, Teixidó C, Viteri S, Gonzalez-Cao M, Riso A, Morales-Espinosa D, Molina MA, Chaib I, Santarpia M, Richardet E, Bria E, Rosell R. Melanoma: oncogenic drivers and the immune system. *Ann Transl Med*. 2015 Oct;3(18):265.
- Loupakis F, Moretto R, Aprile G, Muntoni M, Cremolini C, Iacono D, Casagrande M, Ferrari L, Salvatore L, Schirripa M, Rossini D, De Maglio G, Fasola G, Calvetti L, **Pilotto S**, Carbognin L, Fontanini G, Tortora G, Falcone A, Sperduti I, Bria E. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. *Br J Cancer*. 2016 Jan 12;114(1):30-6.
- Rosell R, Karachaliou N, Chaib I, **Pilotto S**, Bria E, Fernández-Martínez JL, Ramirez JL. Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening. *EBioMedicine*. 2015 Jul 21;2(8):780-1.
- Carbognin L, **Pilotto S**, Milella M, Vaccaro V, Brunelli M, Calio A, Cuppone F, Sperduti I, Giannarelli D, Chilosì M, Bronte V, Scarpa A, Bria E, Tortora G. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. *PLoS One* 2015 PLoS One. 2015 Jun 18;10(6):e0130142.

- Vari S, **Pilotto S**, Maugeri-Saccà M, Ciuffreda L, Cesta Incani U, Falcone I, Del Curatolo A, Ceribelli A, Gelibter A, De Maria R, Tortora G, Cognetti F, Bria E, Milella M. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. *Expert Opin Drug Discov*. 2013 Nov; 8(11): 1381-97.
- Bria e, Di Modugno F, Sperduti I, Iapicca P, Visca P, Alessandrini G, Antoniani B, **Pilotto S**, Ludovini V, Vannucci J, Bellezza G, Sidoni A, Tortora G, Radisky DC, Crinò L, Cognetti F, Facciolo F, Mottolese M, Milella M, Misticò P. Prognostic impact of alternative splicing-derived hMENA isoforms in resected node-negative, non-small-cell lung cancer. *Oncotarget* 2014, vol. 5 (22) pp. 11054-63.
- Bria E, Massari F, Maines F, **Pilotto S**, Bonomi M, Porta C, Bracarda S, Heng D, Santini D, Sperduti I, Giannarelli D, Cognetti F, Tortora G, Milella M. Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. *Crit Rev Oncol Hematol* 2015 vol.93 (1) pp.50-59.
- Buti S, Bordi P, Tiseo M, Bria E, Sperduti I, Di Maio M, Panni S, Novello S, Rapetti SG, **Pilotto S**, Genestreti G, Rossi A, Pezzuolo D, Camisa R, Tortora G, Ardizzoni A. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. *Lung Cancer*. 2015 Jun; 88(3):319-24.
- Carbognin L, Furlanetto J, Vicentini C, Nortilli R, **Pilotto S**, Brunelli M, Pellini F, Pollini GP, Bria E, Tortora G. Neoadjuvant strategies for triple negative breast cancer: 'state of the art' and future perspectives. *Anticancer Agents Med Chem* 2014; 15 (1): 15-25.
- Bria E, Carbognin L, Furlanetto J, **Pilotto S**, Bonomi M, Guarnieri V, Vicentini C, Brunelli M, Nortilli R, Pellini F, Sperduti I, Giannarelli D, Pollini GP, Conte P, Tortora G. Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: sensitivity analysis of randomized trials. *Cancer Treat. Rev*. 2014 vol. 40(7) pp. 847-56.
- Calìo A, Nottegar A, Gilioli E, Bria E, **Pilotto S**, Peretti U, Kinspergher S, Simionato F, Pedron S, Knuutila S, Tortora G, Eccher A, Santo A, Tondulli L, Inghirami G, Tabbò F, Martignoni G, Chilosi M, Scarpa A, Brunelli M. ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. *J Thorac Oncol* 2014, vol. 9(5) pp.729-32.
- Fassan M, Simbolo M, Bria E, Maffacini A, **Pilotto S**, Capelli P, Bencivenga M, Pecori S, Luchini C, Neves D, Turri G, Vicentini C, Montagna M, Tomezzoli A, Tortora G, Chilosi M, De Manzoni G, Scarpa A. High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. *Gastric Cancer* 2014; 17 (3): 442-9.
- Lucchini E, **Pilotto S**, Spada E, Melisi D, Bria E, Tortora G. Targeting the epidermal growth factor receptor in solid tumors: focus on safety. *Expert Opin Investig Saf* 2014 vol.13(5) pp.535-49.
- Bria E, Bonomi M, **Pilotto S**, Massari F, Novello S, Giaj Levra M, Tortora G, Scagliotti G. Clinical meta-analyses of targeted therapies in adenocarcinoma. *Targeted Oncology* 2013 Mar; 8(1): 35-45.
- Bria E, **Pilotto S**, Tortora G. Sorafenib for lung cancer: the 'BATTLE' is still open. *Expert Opin Investig Drugs*. 2012 Oct;21(10):1445-8.
- Bonomi M, **Pilotto S**, Milella M, Massari F, Cingarlini S, Brunelli M, Chilosi M, Tortora G, Bria E. Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. *J Exp Clin Cancer Res*. 2011 Dec 29; 30:115.
- Bria E, **Pilotto S**. Linee guida MASCC-ESMO sull'emesi correlata ai trattamenti antineoplastici: considerazioni e approfondimenti. *Clin Trans Oncol* 2012.

#### **Abstracts, Poster Presentations:**

Several abstracts and posters presented at international and national oncology meeting. Speaker in more than 20 national and international congresses included:

- 11th Congress on Lung Cancer by SLCG (Spanish Lung Cancer Group). Barcellona, November 26 - 27 2015
- IASLC 17th World Conference on Lung Cancer 2016 OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). Vienna December 4 - 7 2016
- IASLC 18th World Conference on Lung Cancer 2017

#### **Scientific affiliations:**

- From 2012: member of AIOM (Associazione Italiana di Oncologia Medica)
- From 2013: young member of ESMO (European Society of Medical Oncology)
- From 2015: young member of IASLC (International Association for the Study of Lung Cancer).
- From 2015: full member ESMO (European Society of Medical Oncology).

- From December 2015: member of the EORTC Lung Cancer Young Investigator

**Main areas of research interest:**

Clinical and translational research on lung cancer and breast cancer, target therapy; immunotherapy; clinical trials methodology.

**MOTHER LANGUAGE**

ITALIAN

*OTHER LANGUAGE*

ENGLISH

- Understanding
  - Writing
  - Speaking

GOOD

GOOD

GOOD

**TECHNICAL SKILLS AND  
COMPETENCE**

Good knowledge Software:  
Microsoft Office.

**LICENSE**

Driving B

I authorize the use of my personal data in accordance with Legal Decree 30 June 2003, No 196 "Protection of personal data" and I assure that the reported information is true.

Signature

Verona, 16<sup>th</sup> January 2018

A handwritten signature in black ink, appearing to read 'A. P. P. P.', is written over a light blue rectangular background.